Dec 9 (Reuters) – Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to ‍expand U.S. production and bolster medicine supply chains.

The site, the third new U.S. facility announced by Lilly, will make small-molecule synthetic and peptide medicines, including orforglipron, its first oral GLP-1 weight-loss drug anticipated to receive U.S. approval early next year.

Global pharmaceutical companies ‌have been increasing U.S. investments after President ‌Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished medicines.

Earlier this year, Lilly outlined plans to spend at least $27 billion on four new U.S. manufacturing sites to counter poten

See Full Page